{"id":251496,"date":"2021-08-12T00:00:00","date_gmt":"2021-08-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidop0040-biopharma-choroideremia-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:42:40","modified_gmt":"2026-03-31T10:42:40","slug":"epidop0040-biopharma-choroideremia-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0040-biopharma-choroideremia-epidemiology-mature-markets\/","title":{"rendered":"Choroideremia &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of choroideremia (<abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr>) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr>, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts one <abbr data-abbreviation-entity=\"7509\" title=\"choroideremia\">CHM<\/abbr> patient population, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases.<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251496","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251496\/revisions"}],"predecessor-version":[{"id":283927,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251496\/revisions\/283927"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}